Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

Amir Iravani joins UCLA Health to lead Theranostics Program

Amir Iravani, a nuclear medicine physician-scientist specializing in molecular imaging and targeted radiopharmaceutical therapies for patients with cancer, has joined UCLA Health where he will serve as director of the Theranostics Program and vice chair of clinical research in the department of nuclear medicine and theranostics.

September 11, 2026

Vol.52 No.33

In Brief

UCLA’s Mina Sedrak receives $3.6M NIH grant to improve recovery and reduce accelerated aging after stem cell transplant

Mina Sedrak, director of the UCLA Center for Cancer and Aging and co-director of Cancer Control and Survivorship Research at the UCLA Health Jonsson Comprehensive Cancer Center, has received a five-year, $3.6 million grant from NIH to develop strategies to improve physical recovery and reduce frailty in older adults following hematopoietic cell transplantation, commonly known as a bone marrow or stem cell transplant.

September 11, 2026

Vol.52 No.33

Clinical Roundup

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

Traditional pathological features used to classify aggressive prostate cancer—such as high-grade disease, cancer extending outside the prostate and cancer involving the seminal vesicles—after surgery do not predict who will benefit more from adding hormone therapy to postoperative radiation, according to a study led by investigators at the UCLA Health Jonsson Comprehensive Cancer Center.

August 14, 2026

Vol.52 No.32

In Brief

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Cristina Puig-Saus, an associate professor of microbiology, immunology and molecular genetics and surgical oncology at the David Geffen School of Medicine at UCLA and an investigator at the UCLA Health Jonsson Comprehensive Cancer Center, and her research team have received a five-year, $3.9 million grant from NCI to develop drug-based strategies that could enhance cancer immunotherapy for patients with melanoma and potentially other types of cancer.

August 07, 2026

Vol.52 No.31

Clinical Roundup

Next-gen CAR-T therapy shows “dramatic and rapid” regression of glioblastoma, Mass General phase I study finds

Just days after a single treatment, patients experienced dramatic reductions in their tumors, with one patient achieving near-complete tumor regression, according to the results of a phase I study conducted by researchers at Mass General Cancer Center.

July 24, 2026

Vol.52 No.29

In Brief

UCLA researchers awarded $3.2M NIH grant to improve detection and treatment of glioblastoma

Researchers from the UCLA Jonsson Comprehensive Cancer Center have been awarded a $3.2 million grant from NIH to develop advanced imaging and surgical strategies aimed at improving outcomes for patients with glioblastoma, a fast-growing and aggressive brain tumor.

June 18, 2026

Vol.52 No.24

Cytokine-armored CAR T-cell therapy helps eliminate aggressive brain tumors in UCLA preclinical study

YOU MAY BE INTERESTED IN

Amir Iravani joins UCLA Health to lead Theranostics Program

UCLA’s Mina Sedrak receives $3.6M NIH grant to improve recovery and reduce accelerated aging after stem cell transplant

Traditional prostate cancer risk factors do not predict hormone therapy benefit, UCLA-led study finds

UCLA researchers receive $3.9M NCI grant to boost the effectiveness of cancer immunotherapy

Next-gen CAR-T therapy shows “dramatic and rapid” regression of glioblastoma, Mass General phase I study finds

UCLA researchers awarded $3.2M NIH grant to improve detection and treatment of glioblastoma

Renew today!

Subscriber content

Never miss an issue!

Login